molybdenum has been researched along with Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aljom, E; Chan, N; Chuang, E; Cigler, T; Donovan, D; Fischbach, C; Fitzpatrick, V; Guillaume-Abraham, J; Kornhauser, N; Lane, ME; Lee, SB; Mittal, V; Moore, A; Nackos, E; Schneider, S; Seo, BR; Vahdat, L; Vallee Cobham, M; Ward, MM; Warren, JD; Wiener, A; Willis, A; Zelkowitz, R | 1 |
| Grigg, A; Karunajeewa, H; Metz, J; Wall, A | 1 |
1 trial(s) available for molybdenum and Neutropenia
| Article | Year |
|---|---|
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
Topics: Adenocarcinoma; Amino Acid Oxidoreductases; Animals; Breast Neoplasms; Cell Line, Tumor; Ceruloplasmin; Chelating Agents; Copper; Disease Progression; Disease-Free Survival; Endothelial Progenitor Cells; Female; Follow-Up Studies; Humans; Lung Neoplasms; Mice, SCID; Molybdenum; Neoplasm Proteins; Neovascularization, Pathologic; Neutropenia; Risk; Triple Negative Breast Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
1 other study(ies) available for molybdenum and Neutropenia
| Article | Year |
|---|---|
Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.
Topics: Adult; Chelation Therapy; Copper; Female; Hepatolenticular Degeneration; Humans; Male; Molybdenum; Neutropenia; Thrombocytopenia | 1998 |